Dexcel Pharma Drug Patent Portfolio
Dexcel Pharma owns 1 orange book drug protected by 1 US patent Given below is the list of Dexcel Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9023391 | Stable benzimidazole formulation | 16 Aug, 2025 | Expired |
Latest Legal Activities on Dexcel Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Dexcel Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 May, 2024 | US10835488 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Oct, 2022 | US9023391 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2022 | US10076494 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Nov, 2020 | US10835488 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Nov, 2020 | US10835488 |
|
Email Notification
Critical
| 29 Oct, 2020 | US10835488 |
|
Issue Notification Mailed
Critical
| 28 Oct, 2020 | US10835488 |
|
Email Notification
Critical
| 13 Oct, 2020 | US10835488 |
| Mailing Corrected Notice of Allowability | 13 Oct, 2020 | US10835488 |
| Dispatch to FDC | 10 Oct, 2020 | US10835488 |
| Corrected Notice of Allowability | 07 Oct, 2020 | US10835488 |
|
Information Disclosure Statement considered
Critical
| 07 Oct, 2020 | US10835488 |
|
Pubs Case Remand to TC
Critical
| 05 Oct, 2020 | US10835488 |
|
Information Disclosure Statement (IDS) Filed
Critical
| 17 Sep, 2020 | US10835488 |
| Quick Path IDS Request | 17 Sep, 2020 | US10835488 |
Dexcel Pharma's Family Patents
Recent FDA approvals and tentative approvals for Dexcel Pharma
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Tofacitinib Citrate |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 16 Dec, 2024 |
Dexcel Pharma Drug List
Given below is the complete list of Dexcel Pharma's drugs and the patents protecting them.
1. Omeprazole
Omeprazole is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9023391 | Stable benzimidazole formulation |
16 Aug, 2025
(4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omeprazole's drug page